IMR Press / EJGO / Volume 38 / Issue 1 / DOI: 10.12892/ejgo3304.2017

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Expressions of H2AX in cervical squamous carcinoma and their clinical significances
J.Y. Ruan1, 2Q. Zhu1, 2L. Mei1, 2H. Wang1, 2, *
Show Less
1 Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China
2 Key Laboratory of Birth Defects and Related Diseases of Women and Children, (Sichuan University), Ministry of Education, Chengdu, China
Eur. J. Gynaecol. Oncol. 2017, 38(1), 65–68; https://doi.org/10.12892/ejgo3304.2017
Published: 10 February 2017
Abstract

Objective: To evaluate the expression and clinical significance of H2AX in cervical squamous carcinoma. Materials and Methods. The expression of H2AX in the cervical squamous carcinoma of 37 patients and in the normal cervical tissue of 15 patients was detected by immuneohistochemical method. Chi-square, correlation analysis, and Kaplan-Meier were utilized to analyze the data. Results: The positive expression rate of H2AX in cervical squamous carcinoma was higher than that in normal cervical tissues (p = 0.016) . The expression of H2AX was negatively correlated with FIGO staging, vaginal invasion, and parametrial infiltration (p < 0.05). Survival analysis showed the expression intensity of H2AX had no significant effect on the prognosis. Conclusion: H2AX was an anticancer protein for cervical squamous carcinoma.
Keywords
Cervical squamous carcinoma
H2AX
Phosphorylate
Immunohistochemistry
Share
Back to top